Effects of ferrous sulphate and non-ionic iron-polymaltose complex on markers of oxidative tissue damage in patients with inflammatory bowel disease.

Abstract

BACKGROUND:

Iron deficiency is a common complication of inflammatory bowel disease. Oral iron therapy may reinforce intestinal tissue injury by catalyzing production of reactive oxygen species.

AIM:

To compare the effects of ferrous sulphate and non-ionic iron-polymaltose complex on markers of oxidative tissue damage and clinical disease activity in patients with inflammatory bowel disease.

METHODS:

Forty-one patients with inflammatory bowel disease and iron deficiency were randomized to treatment with ferrous sulphate 100 mg twice a day or iron-polymaltose complex 200 mg once a day for 14 days.

RESULTS:

Following ferrous sulphate, plasma malondialdehyde increased (P = 0.02), while urine 8-isoprostaglandin F(2alpha) and plasma antioxidants did not change significantly. Iron-polymaltose complex did not change plasma malondialdehyde, urine 8-isoprostaglandin F(2alpha) or plasma antioxidants. Comparing the two treatments, changes in plasma malondialdehyde tended to differ (P = 0.08), while urine 8-isoprostaglandin F(2alpha) and plasma antioxidants did not differ. Neither ferrous sulphate nor iron-polymaltose complex altered clinical disease activity indices.

CONCLUSIONS:

Ferrous sulphate increased plasma malondialdehyde, a marker of lipid peroxidation. Comparing treatment with ferrous sulphate and iron-polymaltose complex, changes in plasma malondialdehyde tended to differ. Clinical disease activity was unchanged after both treatments.

• Authors: K Erichsen, R J Ulvik, T Grimstad, A Berstad, R K Berge, T Hausken
• Journal: Alimentary pharmacology & therapeutics (Aliment Pharmacol Ther) Vol. 22 Issue 9 Pg. 831-8 (Nov 01 2005) ISSN: 0269-2813 [Print] England
• PMID: 16225492 (Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Antioxidants
• Biomarkers
• Ferric Compounds
• Ferrous Compounds
• Hematinics
• Reactive Oxygen Species
• Tablets
• Vasoconstrictor Agents
• 8-epi-prostaglandin F2alpha
• ferrous sulfate
• Malondialdehyde
• Dinoprost
• teferrol

Topics

• Adolescent
• Adult
• Aged
• Antioxidants (analysis)
• Biomarkers (blood)
• Dinoprost (analogs & derivatives, urine)
• Female
• Ferric Compounds (administration & dosage)
• Ferrous Compounds (administration & dosage)
• Hematinics (administration & dosage)
• Humans
• Inflammatory Bowel Diseases (drug therapy)
• Iron Deficiencies
• Male
• Malondialdehyde (blood)
• Middle Aged
• Oxidation-Reduction (drug effects)
• Oxidative Stress (physiology)
• Prospective Studies
• Reactive Oxygen Species (administration & dosage)
• Tablets
• Vasoconstrictor Agents (urine)